Zai Lab (NASDAQ:ZLAB – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Cantor Fitzgerald in a research note issued to investors on Monday, Benzinga reports.
Zai Lab Trading Up 2.1 %
Shares of ZLAB stock traded up $0.37 on Monday, reaching $17.70. 42,868 shares of the stock were exchanged, compared to its average volume of 634,626. The business’s 50 day moving average price is $18.36 and its 200 day moving average price is $20.07. The company has a market capitalization of $1.76 billion, a price-to-earnings ratio of -5.13 and a beta of 1.06. Zai Lab has a twelve month low of $13.48 and a twelve month high of $32.60.
Zai Lab (NASDAQ:ZLAB – Get Free Report) last issued its earnings results on Wednesday, May 8th. The company reported ($0.55) EPS for the quarter, topping analysts’ consensus estimates of ($0.93) by $0.38. Zai Lab had a negative net margin of 116.45% and a negative return on equity of 40.21%. The firm had revenue of $87.15 million during the quarter, compared to the consensus estimate of $77.07 million. During the same quarter in the previous year, the firm posted ($0.51) earnings per share. Equities research analysts forecast that Zai Lab will post -2.78 earnings per share for the current year.
Insider Buying and Selling at Zai Lab
Hedge Funds Weigh In On Zai Lab
Several institutional investors have recently added to or reduced their stakes in ZLAB. Swedbank AB acquired a new position in Zai Lab during the 1st quarter worth approximately $244,000. Tidal Investments LLC acquired a new position in Zai Lab during the 1st quarter worth approximately $334,000. Janus Henderson Group PLC increased its position in Zai Lab by 9.6% during the 1st quarter. Janus Henderson Group PLC now owns 4,428,011 shares of the company’s stock worth $70,924,000 after purchasing an additional 387,729 shares during the period. Bamco Inc. NY increased its position in Zai Lab by 7.3% during the 1st quarter. Bamco Inc. NY now owns 1,599,865 shares of the company’s stock worth $25,630,000 after purchasing an additional 108,991 shares during the period. Finally, Capital World Investors increased its position in Zai Lab by 8.9% during the 1st quarter. Capital World Investors now owns 5,684,180 shares of the company’s stock worth $91,061,000 after purchasing an additional 465,337 shares during the period. Institutional investors and hedge funds own 41.65% of the company’s stock.
Zai Lab Company Profile
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.
Read More
- Five stocks we like better than Zai Lab
- Manufacturing Stocks Investing
- Applied Digital Boosts Stock with Cutting-Edge AI Data Centers
- What is the Hang Seng index?
- Chewy Stock Surges on Roaring Kitty’s Disclosure of Major Stake
- High Flyers: 3 Natural Gas Stocks for March 2022
- How to Invest in Gold: A Complete Guide
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.